BRAF and melanoma: For patients with stage III melanoma harboring a BRAF mutation, one year of adjuvant therapy with dabrafenib plus trametinib or an anti-PD-1 agent (nivolumab or pembrolizumab) significantly prolongs recurrence-free survival (RFS).13–16